Danaher Finalizes $10B Masimo Acquisition to Bolster Diagnostics Portfolio

In a move reflecting the accelerating pace of consolidation within the health technology sector, Danaher Corporation has finalized its acquisition of Masimo Corporation for $10 billion. Masimo will now operate as a standalone, wholly-owned subsidiary within Danaher’s Diagnostics segment, focusing on advanced patient monitoring solutions. Following the completion of the deal on June 10, 2026, Masimo's common stock has officially ceased trading on the Nasdaq exchange.

This acquisition occurs as healthcare giants race to integrate AI-enabled medical devices, placing Danaher in closer competition with peers like Thermo Fisher Scientific, which has also pursued aggressive portfolio expansion. Despite the $10 billion price tag, Danaher maintained its full-year 2026 financial guidance, signaling management's confidence in the merger's immediate accretive potential. Per market data, the valuation reflects a strategic premium consistent with recent high-tier diagnostics and biotech sector acquisitions.

Shares of DHR are currently positioned at $188.41 (as of close June 9, 2026), having traded between a low of $183.75 and a high of $189.21 in the preceding session. Investors should watch for operational integration updates in upcoming quarterly filings, while also monitoring broader market sentiment following recent U.S. Initial Jobless Claims data, which remains a key macroeconomic catalyst for the healthcare equipment industry.